ESC 365 - After peripheral endovascular therapy, DAPT remains the preferred option over dual-pathway antithrombotic therapy: con.

ESC Premium Access

After peripheral endovascular therapy, DAPT remains the preferred option over dual-pathway antithrombotic therapy: con.

Session: Great Debate: antithrombotic therapeutic dilemmas in PAD – dual antiplatelet or dual-pathway antithrombotic therapy?

Topic: Peripheral Vascular and Cerebrovascular Disease

Speaker: Professor M. Brodmann (Graz, AT)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Professor Marianne Brodmann

Medical University of Graz, Graz (Austria)

10 presentations

1 follower

2 more presentations in this session

After peripheral endovascular therapy, DAPT remains the preferred option over dual-pathway antithrombotic therapy: pro.

Speaker: Professor C. Heiss (Guildford, GB)

Great Debate: antithrombotic therapeutic dilemmas in PAD – dual antiplatelet or dual-pathway antithrombotic therapy? – discussion.

Speaker: Professor I. Baumgartner (Bern, CH)

Access the full session

Great Debate: antithrombotic therapeutic dilemmas in PAD – dual antiplatelet or dual-pathway antithrombotic therapy?

Speakers: Professor M. Brodmann, Professor C. Heiss, Professor I. Baumgartner

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by